Ci-1040 (Not yet branded)
Other Medications
Description
CI-1040 is a small molecule MEK inhibitor that targets the mitogen-activated protein kinase (MAPK) pathway in colorectal cancer treatment. This compound specifically inhibits MEK1 and MEK2 kinases, which are critical components of the RAS/RAF/MEK/ERK signaling cascade frequently dysregulated in colorectal malignancies. CI-1040 was developed to block tumor cell proliferation and survival signals in advanced colorectal cancer patients, particularly those with RAS pathway mutations.
Mechanism of Action
CI-1040 works by selectively binding to and inhibiting MEK1 and MEK2 kinases, preventing the phosphorylation and activation of downstream ERK1/2 proteins. This inhibition disrupts the RAS/RAF/MEK/ERK signaling pathway, leading to decreased tumor cell proliferation, increased apoptosis, and reduced angiogenesis in colorectal cancer cells with aberrant MAPK pathway activation.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.